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Abstract
Background: Intrahepatic cholangiocarcinomas (ICC) are relatively rare malignant tumors associated with a poor
prognosis. Recent studies using genome-wide sequencing technologies have mainly focused on identifying new
driver mutations. There is nevertheless a need to investigate the spectrum of copy number aberrations in order to
identify potential target genes in the altered chromosomal regions. The aim of this study was to characterize the
patterns of chromosomal copy-number alterations (CNAs) in ICC.
Methods: 53 patients having ICC with frozen material were selected. In 47 cases, DNA hybridization has been
performed on a genomewide SNP array. A procedure with a segmentation step and a calling step classified genomic
regions into copy-number aberration states. We identified the exclusively amplified and deleted recurrent genomic
areas. These areas are those showing the highest estimated propensity level for copy loss (resp. copy gain) together
with the lowest level for copy gain (resp. copy loss). We investigated ICC clustering. We analyzed the relationships
between CNAs and clinico-pathological characteristics.
Results: The overall genomic profile of ICC showed many alterations with higher rates for the deletions. Exclusively
deleted genomic areas were 1p, 3p and 14q. The main exclusively amplified genomic areas were 1q, 7p, 7q and 8q.
Based on the exclusively deleted/amplified genomic areas, a clustering analysis identified three tumors groups: the first
group characterized by copy loss of 1p and copy gain of 7p, the second group characterized by 1p and 3p copy losses
without 7p copy gain, the last group characterized mainly by very few CNAs. From univariate analyses, the number of
tumors, the size of the largest tumor and the stage were significantly associated with shorter time recurrence. We
found no relationship between the number of altered cytobands or tumor groups and time to recurrence.
Conclusion: This study describes the spectrum of chromosomal aberrations across the whole genome. Some of the
recurrent exclusive CNAs harbor candidate target genes. Despite the absence of correlation between CNAs and
clinico-pathological characteristics, the co-occurence of 7p gain and 1p loss in a subgroup of patients may suggest a
differential activation of EGFR and its downstream pathways, which may have a potential effect on targeted therapies.
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Background
Intrahepatic cholangiocarcinomas (ICC) are malignant
tumors arising from intra-hepatic bile duct epitheliums,
either from large or small bile ducts. ICC is a relatively
rare malignant tumor but represents around 10% of the
primary hepatic malignancies worldwide [1]. There is a
dramatic geographic disparity for the incidence rates of
ICC that mainly correlates with difference in environ-
mental risk factors. The highest incidence is observed for
Asian countries in areas with liver fluke endemic infec-
tion. In western countries, the age-adjusted incidence and
mortality of ICC have increased over the last decades [2-5]
and classical risk factors reported in the literature are
chronic biliary tract disorders such as primary scleros-
ing cholangitis, biliary-duct cysts, hepatolithiasis. Others
non-biliary related conditions have also been discussed
[1,6]. A recent meta-analysis reported [5] that cirrhosis,
chronic hepatitis B and C, alcohol use, diabetes and obe-
sity are risk factors for ICC. However, for the majority of
the patients, no risk factor can be identified.
For most of the patients, the disease remains asymp-
tomatic or paucisymptomatic for a long period of time
and is diagnosed at advanced stages which leads to a
poor prognosis. Surgical resection or liver transplantation
represent the only curative options that can be offered
to a fraction of the patients. In some locally advanced
cases, surgery may be proposed after primary systemic
chemotherapy or portal vein embolization. After curative
resection, there is a high rate of relapse that favors the use
of adjuvant therapies. Nevertheless, the wide patient-to-
patient variability in tumor characteristics and outcomes
raises a challenge for refining the use of innovative adju-
vant therapy.
Recent advance in genomic science has offered new
opportunities for deciphering cancer diseases and iden-
tifying molecular prognostic or predictive markers. In
practice, these genomic technologies provide a means of
finding novel actionable targets and defining new thera-
peutic strategies based on molecular classifications. For
several solid tumors, such as lung and colon carcinomas,
the use of targeted therapy has leaded to major changes
in the management of patients. Despite major recent
genomic studies, the molecular portrait of ICC remains
incomplete with few actionable genomic abnormalities
but some new early phase clinical trials with targeted
therapies are currently underway [7,8].
Before the widespread use of high throughput genomic
technologies, published studies on cholangiocarcinomas
have focused on a limited number of genetic alter-
ations and reported mutations in KRAS, TP53, SMAD4,
CDKN2A, CDH1 or BRAF genes [9-13]. High level ampli-
fications of HER2 and CyclinD1 and overexpression of
MET have been also described in few cases [14-17]. How-
ever, the series were often heterogeneous (mixing intra
and extra-hepatic cases) and of small sample size which
may explain the wide variations in prevalence reported for
these alterations.
In the recent years, a tremendous effort has been made
to investigate molecular alterations of ICC using genome-
wide technologies. Among them, two gene expression-
based classifications have been published [18,19]. From
a series of 104 surgically resected cholangiocarcinomas
(not restricted to intrahepatic cases), Anderson et al.
[18] proposed a gene expression signature that identi-
fied a high risk group of patients. The most malignant
phenotype was characterized by up-regulation of the tyro-
sine kinase signaling pathways (HER2, EGFR, MET). In
another study, Sia et al. [19] analyzed a series of 149
archived formalin-fixed tumor tissues and reported the
presence of two distinct transcriptional classes: the so-
called inflammation class characterized by activation of
inflammatory signaling pathways and the so-called pro-
liferation class characterized by activation of oncogenic
signaling pathways (including EGFR and MET), the latter
being associated with a worse outcome.
From a genome-centered perspective, recent series
aimed to find new so-called driver mutations using either
targeted or whole-genome/exome sequencing technolo-
gies. Differences regarding the sequencing strategies and
the tissue preservation methods (frozen or formalin-fixed
paraffin-embedded material) may explain some discrep-
ancies between the reported frequencies of driver muta-
tions. The most frequent mutations are found in either
classical tumor-associated genes (KRAS, TP53, PTEN,
BRAF) or newly reported genes such as: IDH1/2, BAP1,
ARID1A, ERRFI1, PBRM1 [20-29]. Fusions have also been
demonstrated for FGFR2 gene [21,30]. In a study compar-
ing fluke and non-fluke associated cholangiocarcinomas
[28], Chan-on et al. reported a higher frequency of BAP1
and IDH1/2 in non-fluke associated cases. In these latter
group, the authors showed the existence of a lower overall
mutation burden. This finding raised the question of dif-
ferent mechanisms of biliary carcinogenesis. In the same
study, Chan-on et al. also investigated copy number alter-
ations (CNAs) from a small subset of 15 non-O. Viverrini
cholangiocarcinomas and observed multiple alterations
that emphasized the potential role of CNAs in biliary
carcinogenesis.
To date, few studies have analyzed whole-genome CNAs
in ICC [7,8]. Among them, Ross et al. [26] described focal
amplifications of MCL1 and MET. Sia et al. [19] identified
frequent CNAs and reported the poor outcome associ-
ated with 14q22.1 deletion. It is worth noting that both
series have been performed on paraffin-embedded mate-
rial. The use of this material has the great advantage of
allowing analysis of large retrospective series but leads to
underestimate the occurrence of low-level copy-number
alterations. This is particularly challenging for this tumor
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type which is often characterized by the presence of an
abundant stroma reaction.
In order to characterize the patterns of chromosomal
alterations in ICC, we conducted a genome-wide CNAs
study using frozen material in a surgical series of patients
with ICC.We evaluated the relationships between clinico-
pathological characteristics and copy number changes.
Methods
Patients and samples
The study included 53 patients with intrahepatic cholan-
giocarcinoma who underwent surgical resection with
curative intent from 2003 to 2009 at the Centre Hépato-
Biliaire (Hepatinov, Villejuif, France). Informed consent
was obtained for each patient. Retrospective collection
of clinical data was approved by the Comité d’éthique
du Groupe Hospitalier Paris-Sud. Patient demograph-
ics, symptoms, anamnesis, operative data, tumor pathol-
ogy and disease recurrence were obtained from hospital
medical records. Stage grouping was assessed a posteri-
ori, by using the AJCC/UICC TNM (7th edition) [31].
Tumor samples were immediately snap frozen and stored
at −80◦C until retrieved. All frozen samples underwent
pathological examination by an experienced pathologist
(CG). Samples that contained a minimum of 20% of tumor
cells were used in the analyses whereas the remaining
cases were used as negative controls.
DNA extraction was performed using PureLink
Genomic DNA Mini Kit (Invitrogen, Camarillo, CA,
USA) and were hybridized on Infinium HumanExome
BeadChip (Illumina Inc., San Diego, CA, USA), accord-
ing to the manufacturer’s specifications. All experiments
were performed at the P3S Pateform UPMC, Paris,
France). The exonic content of the HumanExome chip
consists of more than 250,000 markers focusing on exonic
regions. Only 47 high-quality samples were hybridized.
The genome-wide analysis has been performed on 42
samples (≥ 20% of tumor cells).
Statistical analysis of SNP array data
The arrays were scanned with an iScan system [32]. We
used the intensity signals obtained from a total of 242,296
exonic autosomal probes. Normalized log R Ratio (LRR)
and B allele frequencies (BAF) were obtained from Bead-
Studio [32] as described in [33].
CNA calling procedure
Various methods have been proposed to study CNAs
using SNP arrays but the final calling step still remains a
challenging task, especially in tumors with a high stromal
content. For this study, we have implemented a tree-based
algorithm to classify genomic regions into four meaning-
ful and easily interpretable CNA states: copy loss (Loss),
copy neutral (Neutral), copy gain (Gain) and copy neutral
loss of heterozygosity (CNLOH or copy neutral allelic
loss).
The basic two consecutive steps of the procedure are
the segmentation step (identification of the breakpoints
in the data) and the calling step (allocation of the seg-
ments to one of the CNA states). For the segmentation
step, the data were processed using a joint segmentation
of the bivariate signal (LRR and BAF) [34]. Broadly speak-
ing, a recursive binary segmentation [35] has been used to
identify a list of candidate breakpoints and the final seg-
mentation has been obtained from a pruning step using
dynamic programming [36]. For the calling step, we con-
sidered a tree-based algorithm (summarized in Figure 1)
with five decision nodes allowed to assign each segment
a CNA state. The BAF values were used at two decision
nodes (labeled (1) and (2)) to distinguish segments with
a loss of heterozygosity (LOH), segments with an even
number of copies for both alleles or segments with an odd
number of copies. The LRR values were used at three deci-
sion nodes (labeled (3), (3’) and (3”)) to classify segments
as copy loss, copy neutral or copy gain. The decision nodes
are described in more details below.
To identify heterozygous SNPs, a kernel estimate of the
BAF density has been considered. The two extreme val-
ues (i.e. the closest to zero and one) corresponding to
local minima, were used as thresholds to exclude homozy-
gous SNPs. For each segment (decision node labeled (1)
in Figure 1), a binomial test was performed to identify
loss of heterozygosity (segments for which the propor-
tion of heterozygous SNPs was significantly lower than
the proportion estimated for the whole genome). For seg-
ments without LOH, it was expected that even (resp. odd)
copy number values were giving rise to unimodal (resp.
bimodal) BAF distribution. Thus, in order to identify these
two types of segments, a combination of the Hartigan’s dip
test of unimodality [37] and the Wilcoxon test was per-
formed. In practice, if one of the two tests was significant,
the segment was considered as having odd copy number
values (decision node labeled (2) in Figure 1).
Segments with even copy number values can be clas-
sified as either copy neutral or copy gain (with at least
two additional copies). To detect these copy gains, LRR
medians were computed for all segments having even copy
number values. The copy gains, giving rise to extreme
values, were detected by a Grubbs’ test for outliers (deci-
sion node labeled (3) in Figure 1). In contrast, segments
having odd copy number values can be classified as copy
loss, copy gain or CNLOH (either mixture of normal
cells or tumoral heterogeneity). Based on the LRR values
corresponding to copy neutral segments identified previ-
ously (at decision node labeled (3)), an equivalence test
was performed to identify CNLOH segments. Then, the
remaining segments were classified as copy gain (resp.
loss) if the LRR median was greater (resp. lower) than the
Dalmasso et al. BMC Cancer  (2015) 15:126 Page 4 of 11
Figure 1 Flowchart of the calling algorithm used to classify each segment. Steps (1) and (2) are based on the BAF values while the final calling
(steps (3), (3’) and (3")) is based on the LRR values.
copy neutral LRR median (decision node labeled (3’) in
Figure 1). Finally, to distinguish CNLOH from LOH with
copy number changes, one-sided Wilcoxon tests were
performed for each segment with loss of heterozygosity
(decision node labeled (3”) in Figure 1).
To take into account themultiple testing problem result-
ing from the large number of statistical tests that are
performed for the whole procedure, we considered a
weighted Bonferroni procedure. The adjusted level used
for each segment is defined as
∑
ni
ni α (where ni is the
segment size). Then, these adjusted levels are divided by
the maximum number of statistical test that may be per-
formed for each segment. The family wise error rate for
the whole procedure is then controlled at an α level of 5%.
For the clustering and association analyses and in order
to summarize genomic information while keeping a suffi-
cient level of resolution, copy number states was inferred
from applying the majority voting procedure based on
their cytoband location according to the Human NCBI
Genome Build 37.1 In total, 768 cytobands were analyzed.
Chromosomal cytoband aberration patterns
The aim of this analysis was to identify patterns of
recurrent CNAs considering jointly the chromosomal
propensity for deletion and amplification. More precisely,
our interest was to select recurrent so-called exclusively
deleted (resp. amplified) cytobands that were those with
the highest level for copy loss (resp. copy gain) together
with the lowest level for copy gain (resp. copy loss).
This choice relied on the hypothesis that these exclusive
behaviors reflect a selective advantage for tumor growth
for one state (e.g. copy loss) associated with a selective
disadvantage of the converse state (e.g. copy gain).
In order to represent the cytoband’s propensity for the
occurrence of either copy loss or copy gain across all the
ICC tumor samples, we considered a multi-class model-
based approach that describes the joint propensity of a
given cytoband for being deleted/unmodified/amplified
[38]. Broadly speaking, the latent model describes
nine classes (3 × 3) that corresponds to three levels
(low/medium/high) of copy loss and copy gain. The allo-
cation of a cytoband to one of the nine classes was per-
formed using the Bayes classification rule that assigned
each cytoband to the class to which it had the highest
probability of belonging. The final results of this analysis
is a set of exclusively deleted and amplified cytobands.
In order to determine if these exclusively deleted and
amplified cytobands were able to identify clusters of
tumor samples, we considered a model selection proce-
dure which infers the unknown number of tumor clusters
using the most relevant subset of exclusively deleted and
amplified cytobands [39]. We selected the model that
gave the optimal number of tumor samples together with
the optimal set of relevant cytobands according to the
Bayesian information criterion.
General statistical methodology
In order to increase the statistical power of the association
analysis between CNAs and clinico-biological parameters,
the few copy losses of a cytoband considered as exclusively
amplified were gathered with those having a modal sta-
tus. The converse was also done for a cytoband considered
as exclusively deleted. For each cytoband, the relation-
ships between clinico-pathologic features and CNAs were
assessed using either the Pearson’s chi-squared test with
Yates’ correction for continuity (categorical variables) or
Dalmasso et al. BMC Cancer  (2015) 15:126 Page 5 of 11
the analysis of variance (continuous variables with log-
transformation). The null hypothesis is that the CNA
distribution is the same for all the modalities (or levels) of
the variable of interest.
Relapse-free survival (RFS) was calculated from the
date of diagnosis until date of first relapse or last
follow-up examination. All other events were censored.
Kaplan-Meier analysis was carried out to generate
RFS curves. Univariate proportional hazard model (Cox
model) analysis was performed to assess the prognostic
influence of clinical and biological variables. For the anal-
ysis of the set of cytobands and to address the multiple
testing problem, we controlled the family wise error rate
at an α level of 5%. Analyses were performed with R 2.15.3
software [40].
Results and discussion
Clinical characteristics
The median age at diagnostic was 60 years (range: 27-
81). 28 patients were men. Among the 53 patients, the
following potential etiological factors were obtained from
patients’ anamnesis: hemochromatosis (two patients), pri-
mary sclerosing cholangitis (one patient), hepatitis HCV-
related liver cirrhosis (one patient),Wilson disease-related
cirrhosis (one patient). Additionally, pathological exami-
nation of the non tumoral liver tissue has found cirrho-
sis in three patients, sclerosing cholangitis histological
lesions in two patients. One patient, having a history
of HBV infection, was diagnosed with a biliary cystade-
nocarcinoma arising in a cystadenoma. No patient was
known to have had prior exposure to liver flukes. Most
of our patients (42/53) did not show any pre-existing liver
disease, concordant with the literature [41].
Symptoms of biliary obstruction were observed in eight
cases at the time of diagnosis. Surgery was performed after
portal vein embolization in 12 cases and after primary
chemotherapy in 20 cases. From the latter, significant
regression fibrosis was observed in three cases on his-
tological examination. We decided then to analyze for
genomic analyses the whole series as a homogeneous
group. The surgical treatment was segmentectomy (5
patients), transplantation (3 patients) and hemihepatec-
tomy or extended hemihepatectomy for the remaining
patients. Lymph node evaluation has been performed in
33 cases.
From macroscopic examination, the median speci-
men weight was of 670 grams (range: 78-2,653). The
median tumor size was 8.0 cm (range: 2.3-25.0). Twenty-
seven patients had multiple tumors, including 20 patients
with more than three nodules. Eleven patients had
macrovascular invasion. Macroscopic intraductal growth
was observed in eight specimens. Thirty-two patients
had surgical margin infiltration. Histology showed well
differentiated adenocarcinomas in 16 cases.
With the exception of five papillary carcinomas and two
sarcomatoid carcinomas, most of the samples were diag-
nosed as tubular adenocarcinomas. Histological vascular
invasion and perineural infiltration were observed in 29
over 48 patients and 11 over 43 patients, respectively.
From the medical records, the stage has been evaluated
according to the AJCC/UICC 7th edition for 52 patients:
stage I (6/52, 11%), stage II (31, 60%), stage III or IV (15,
29%).
The median time to recurrence was 19 months. The
relapse-free survival rate was 46.2% (95% confidence inter-
val: 33.0%-64.7%) at 24 months.
Calling procedure
In five cases with no or very few tumor cells, we observed
no CNA which reflects the high specificity of our proce-
dure. We tested the relationship between CNAs and the
percentage of tumor cells distributions across the tumor
samples. There was no significant relationship (p=0.40)
between the fraction of the genome altered (copy loss or
gain) and the percentage of tumor cells which reflects the
good behavior of our classification procedure for the cho-
sen cut-off (20% of tumor cells). Figure 2 displays BAF
and LRR values together with the allocation states for four
samples with different proportions of tumoral cells con-
tents: less than 20% (top left panel), 30% (top right panel),
40% (bottom left panel) and 60% (bottom right panel).
Copy neutral, copy gain, copy loss and CNLOH are in gray,
pink, blue and green, respectively. From this figure, we can
see the interest of considering simultaneously BAF and
LRR values for the calling procedure. Out of the 42 cases
analyzed, 15 tumors showed some copy-neutral events
with very few recurrent event (less than three).
Landscape of copy number alterations
In the following, we report the pattern of cytoband aber-
rations across the entire genome. Themedian rate of cyto-
band CNAs per patient was of 27.4% (range 0%-70.8%).
Figure 3 displays the frequencies of copy losses and copy
gains across the whole genome from 1pter to 22qter. From
visual inspection, the frequency rates of deleted cytobands
were higher than those of amplified cytobands. The global
CNAs portrait is broadly concordant with previous series
[19,42].
Results of the chromosomal cytoband pattern analysis
are shown in Table 1 that displays, for the nine classes, the
joint estimated average probabilities for copy loss, neu-
tral and copy gain. Probability for copy gain ranges from
0.9% to 26.8% whereas for copy loss it ranges from 10.2%
to 69.3%. Applying the Bayes classification rule, 42 (5.9%)
genomic cytobands were classified as exclusively deleted
and 98 (12.8%) as exclusively amplified. An exclusively
deleted cytoband has the highest frequency for copy loss
(69.3%) together with the lowest frequency for copy gain
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Figure 2 LRR values and BAF values all along the 22 autosomes for four samples with different proportions of tumoral cells: less than
20% (top left panel), 30% (top right panel), 40% (bottom left panel) and 60% (bottom right panel). Copy neutral, copy gain, copy loss and
CNLOH are in gray, pink, blue and green, respectively.
(0.9%). An exclusively amplified cytoband has the highest
frequency for copy gain (26.8%) together with the lowest
frequency for copy loss (10.2%).
In the following, we will focus on genes located on
either exclusively deleted or exclusively amplified cyto-
bands. These exclusively deleted and amplified cytobands
are reported in Table 2 with their corresponding mean
percentage of copy loss and copy gain over the genomic
area. The exclusively deleted cytobands were observed on
1p36.33-1p35.1, 3p26.3-3p14.25 and 14q24.1-14q32.33. It
is worth noting that the 6q deleted area was not consid-
ered as exclusively deleted since this genomic area showed
a medium level of amplification. The exclusively ampli-
fied cytobands were observed on 1p11.2-1p41.1, 1q21.1-
1q44, 2q23.1-2q35, 7p22.3-7p11.1, 7q11.1-7q36.3 and
8q23.2-8q24.3.
The highest exclusively deleted cytobands were located
in the terminal region of the short arm of chromosome
1 (1p36.33-1p35.1). This genomic region is deleted in
numerous carcinomas but the impressive high rate of
deletion in our series (range: 57.1-71.4%) may raise the
issue of specificity for our calling procedure. However, the
absence of CNAs detected in five cases having no or very
few tumor cells as well as the absence of CNAs detected
in normal samples analyzed in the same batch (data not
shown) support the good specificity of our method. Sia
et al. [19] reported a lower rate of copy loss (16%) but
this result refers to the deletion of the whole short arm
of chromosome 1. In their supplemental data, the high
rate of the 1p36.32 to 1p35.2 focal region is concordant
with our findings. The loss of 1pter region is not spe-
cific of non-fluke ICC since it has also been reported as
the most frequent genomic aberration in fluke-associated
ICC [43]. Four candidate tumor suppressor genes RUNX3,
ARID1A, ERRFI1 and mTOR, all located on this exclu-
sively deleted area, are of interest.
RUNX3 encodes a member of the runt domain-
containing family of transcription factors and is consid-
ered as a tumor suppressor gene. Dachrut et al. [43]
showed an inhibition through hypermethylation, associ-
ated with a decreased expression of the protein, suggesting
the role of this protein in fluke associated carcinogene-
sis. ARID1A has emerged as a tumor suppressor gene,
mutated in a broad spectrum of cancers, including ovar-
ian clear cell, endometrioid, gastric and colon carcinomas.
ARID1A gene plays the role of a gatekeeper (regulating
cell cycle progression), but also of a caretaker (prevent-
ing genomic instability) [44]. ARID1A mutations result
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Figure 3 Frequencies of chromosomal aberrations. The frequencies of amplification (light pink) and deletion (light blue) over the ICC samples
are plotted and ordered, according to the chromosomal order (x-axis) from 1 pter to 22 qter. Exclusively deleted and amplified cytobands are
underlined in purple.
in loss of ARID1A-protein expression. It frequently co-
occurs with PI3K/AKT-pathway activation and is asso-
ciated with mismatch repair deficiency in colon cancer
[45]. In a recent study, it has been shown that ARID1A-
deficient cancer cells require the PI3K/AKT pathway and
have an increased sensitivity to treatment targeting this
pathway [46]. ARID1A is mutated in more than 10% of
cholangiocarcinomas and is associated with copy loss of
Table 1 Joint estimated probabilities of copy loss (L)/copy
neutral (N)/copy gain (G) for the 9 classes
Low Medium High
Low L:13.6%, N:83.9%, L:35.0%, N:63.1%, L:69.3%, N:29.8%,
G:2.5% G:1.9% G:0.9%
Medium L:12.1%, N:75.2%, L:32.2%, N:58.0%, L:66.5%, N:28.6%,
G:12.7% G:9.8% G:4.9%
High L:10.2%, N:63.0%, L:28.0%, N:50.5%, L:62.0%, N:26.6%,
G:26.8% G:21.5% G:11.4%
The three percentages given in each cell represent the frequency of copy
loss/neutral/gain, respectively. The results for the exclusively deleted and
amplified classes are in bold.
the genomic area [28]. ERRFI1 gene acts as a negative reg-
ulator for several EGFR family members, including EGFR
and ERBB2 through direct interaction with the kinase
domains of these proteins. Downregulation of ERRFI1
has been demonstrated in breast cancer and glioblastoma
and more recently in a single case of cholangiocarci-
noma [21]. Interestingly, the authors have shown that this
patient underwent a rapid regression when treated with
an EGFR inhibitor. It is worth noting that deletion of
the 1p genomic area leads to a copy loss of the mTOR
gene (1p36.22), encoding for a serine/threonine protein
kinase which acts as a major downstream effector of the
PI3K/AKT pathway.
The second exclusively deleted genomic area was
3p26.3-3p14.25. Two candidate genes (BAP1 and PBRM1)
were located on this region. BAP1 (BRCA1-associated
deubiquitylase) has been recently identified as a tumor
suppressor gene, which promotes repair of DNA double-
strand breaks, enhancing cell survival after DNA dam-
age. BAP1 is mutated in several cancer types, including
non-fluke ICC [28]. PBRM1 is involved in transcriptional
activation and repression by chromatin remodeling and
mutations have been found in ICC [29].
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Table 2 CNA pattern of genomic areas exclusively deleted
or amplified
Mean% of copy Mean% of copy
loss gain
Exclusively deleted cytobands
1p36.33-1p35.1 67.5% 1.0%
3p26.3-3p14.25 57.7% 3.4%
14q24.1-14q32.33 52.6% 0.0%
Exclusively amplified cytobands
1p11.2-1p41.1 4.8% 17.9%
1q21.1-1q44 7.5% 29.5%
2q23.1-2q35 7.8% 20.2%
7p22.3-7p11.1 11.0% 24.7%
7q11.1-7q36.3 9.6% 22.6%
8q23.2-8q24.3 6.8% 22.6%
The average percentages for copy loss and copy gain are display for each
genomic area.
Surprisingly, the exclusively deleted 14q24.1-14q32.33
area harbors the AKT1 gene which is a serine/threonine
kinase and plays a key role in cell deregulation as a down-
stream mediator of the KRAS/PI3K pathway. Our results
are concordant with those from Sia et al. series [19], show-
ing copy loss of 14q in 36% of the cases. It is worth noting
that, in a lung cancer mice model, it has been shown
that AKT1 deletion may prevent tumorigenesis by mutant
KRAS [47].
The highest exclusively amplified genomic was 1q21.1-
1q44. Gain of chromosome 1q copy is one of the most
frequently detected alterations in hepatocellular carci-
noma and has also been reported in cholangiocarcinomas.
Some potential target genes (e.g. CHD1L) located on 1q21
have been recently reported [48].
The exclusively amplified genomic area 2q23.1-2q35
harbors IDH1 gene (Isocitrate Dehydrogenase 1). Gain of
function mutations of the IDH1, leading to DNA methy-
lation perturbation, have been reported in non-fluke ICC
[21,28,29]. Our results raise the question of the potential
role of amplification in IDH1 activation.
Figure 4 Heatmap of the tumor samples for exclusively deleted and amplified cytobands. The color coding for the matrix data is: copy loss
(light blue), copy neutral (light yellow) and copy gain (pink). Three tumor clusters are indicated on the left side in orange (first class), light green
(second class) and gray (third class). Cytoband clusters are shown on the top: dark green (1p), light green (1q), red (2q), purple (3p), blue (dark blue
for 7p, light blue for 7q), orange (8q) and gray (14q).
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The whole chromosome 7 was amplified in eight cases
which suggests a mechanism of aneuploidy. The chromo-
some 7 harbors numerous oncogenes, including: EGFR,
MET, BRAF as well as the newly identified candidate
KMT2C (MLL3). Mutating activation of EGFR [49], BRAF
[11] as well as overexpression of MET [50] have been
described in biliary carcinogenesis. It is interesting to note
that the KMT2C (MLL3) gene is considered as a tumor
supprossor gene and inactivating mutations have been
reported in fluke-associated cholangiocarcinomas [28]. In
our series, only five cases showed a deletion of the 7q36.1
cytoband harboring the KMT2C (MLL3) gene. The rela-
tionship between KMT2C (MLL3) mutation and copy
number remains to be investigated.
The exclusively amplified cytoband 8q24.21 harbors
MYC gene. It encodes for a nuclear protein which func-
tions as a transcription factor that activates multiples
genes and pathways. MYC has been shown to be activated
by amplification in multiples carcinomas.
We also analyzed how the tumor samples could be clas-
sified based on the minimal subset of exclusively deleted
and amplified cytobands. The aim of this molecular clas-
sification was to identify tumor clusters defined by the
smallest subset of exclusively deleted and amplified cyto-
bands. The best model (according to the BIC criterion)
corresponded to the one that led to three tumor clusters.
Figure 4 shows a heatmap of the tumor samples for the
exclusively deleted/amplified cytobands. Ten tumors are
classified in the first cluster (orange in Figure 4) character-
ized by copy loss of 1p and copy gain of the short arm of
chromosome 7. Twenty tumors are classified in the second
cluster (ligth green in Figure 4) characterized by 1p and 3p
copy losses and no 7p copy gain. Twelve tumors are classi-
fied in the third cluster (gray in Figure 4) characterized by
no or very few alterations.
It is worth noting that all the cases of the first cluster,
having copy gains of chromosome 7 showed also 1p copy
loss.Wemay hypothesize that this tumor cluster is charac-
terized by an activation of Growth Factor Receptors EGFR
and MET (by chromosome 7 copy gain), amplified by the
silencing of ERRFI1 (through 1p copy loss), a powerful
negative regulator of several EGFR family members.
Association between CNAs and pathological factors and
RFS analysis
For each the exclusively deleted and amplified cyto-
bands, we analysed the relationships between CNAs
and the main pathological factors : size of the largest
tumor, tumor number (single vs multiple), macrovascu-
lar invasion, histological vascular invasion and intraneural
invasion, pathological stage and primary chemotherapy.
After adjustment for multiplicity testing, none of these
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Figure 5 Recurrence free survival (RFS) analyses for the entire series of patients (upper left) and according the main clinico-pathological
factors: multiple versus unique tumors (upper right), pTNM stage (lower left) and primary chemotherapy (lower right).
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factors were associated with the distribution of the CNAs.
Moreover, none of these clinico-pathological factors were
associated with the total number of altered cytobands or
the three tumor clusters.
From univariate survival analysis, we found no rela-
tionship between time to recurrence and age (p=0.22)
gender (p=0.14), histological differentiation (p=0.94), vas-
cular (p=0.58), intraneural invasion (p=0.87), macrovas-
cular invasion (p=0.57), resection margins (p=0.61). In
contrast, multiple tumors (p=0.02), size of the largest
tumor (p=0.04), pTNM 7th edition (I vs. II-III-IV, p=0.03),
were significantly associated with shorter time recurrence
(Figure 5). In the group of advanced ICC (stage II-III-IV),
primary chemotherapy was associated with a lower rate of
recurrence (p=0.03).
We found no relationship between the total number of
altered cytobands and the time to recurrence. We found
no relationship between the three tumor clusters and
the time to recurrence. We also found no relationship
between time to recurrence and the 11q13.2 copy gain
(p=0.37) or 14q22.1 copy loss (p=0.18) reported by Sia
et al. [19].
In this work, we have selected a set of intrahepatic
cholangiocarcinomas, from frozen material. This selec-
tion leaded to a relatively small sample size, which lim-
its the statistical power of our analyses. This limitation,
inherent to the rarity of this tumor, advocates for multi-
institutional studies.
Conclusion
This work describes the chromosomal CNA patterns of
a series of ICC. We observed numerous copy number
alterations in most of the samples with a high rate of
exclusive deletion encompassing 1p, 3p and 14q. We
also observed recurrent amplification for 1q, 7p, 7q and
8q. Some of these CNAs harbor candidate target genes.
The co-occurence of copy gain of chromosome 7 and
copy loss of 1p in a subset of tumor samples sug-
gests an activation of EGFR receptor family together
with a downregulation of the PI3K/AKT/mTOR path-
way, raising the question of a potential sensibility of
this subgroup to EGFR inhibitors or to therapies that
target more specifically the RAS/MAPK signaling path-
way. We do not find any relationship between CNAS
and the clinico-pathological factors or the recurrence-free
survival.
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